The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
Level | Code | Title | |
---|---|---|---|
1 | R | Respiratory system | |
2 | R05 | Cough and cold preparations | |
3 | R05C | Expectorants, excl. combinations with cough suppressants | |
4 | R05CA | Expectorants | |
5 | R05CA03 | Guaifenesin |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
Route | Amount |
---|---|
ORAL - Oral | 0.9 g |
PAREN - Parenteral | 0.9 g |
Active Ingredient | Description | |
---|---|---|
Guaifenesin |
Guaifenesin is an expectorant the action of which promotes or facilitates the removal of secretions from the respiratory tract. The precise mechanism of action of guaifenesin is not known; however, it is thought to act as an expectorant by increasing the volume and reducing the viscosity of secretions in the trachea and bronchi. In turn, this may increase the efficiency of the cough reflex and facilitate removal of the secretions. Guaifenesin is over-the-counter drug for the treatment of cough and common cold. |
Title | Information Source | Document Type | |
---|---|---|---|
LEMSIP CHESTY COUGH Oral solution | Health Products Regulatory Authority (IE) | MPI, EU: SmPC | |
ROBITUSSIN CHESTY COUGH MEDICINE Oral solution | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.